Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Recently, we synthesized and characterized the first selective V1b vasopressin (VP)/oxytocin receptor agonist, d[Cha4]arginine vasopressin. However, this agonist was only selective for the human receptors. We thus decided to design a selective V1b agonist for the rodent species. We started from previous observations showing that modifying [deamino1,Arg8]VP in positions 4 and 8 altered the rat VP/oxytocin receptor selectivity. We synthesized a series of 13 [deamino1,Arg8]VP analogs modified in positions 4 and 8. Among them, one seemed very promising, d[Leu4, Lys8]VP. In this paper, we describe its pharmacological and physiological properties. This analog exhibited a nanomolar affinity for the rat, human, and mouse V1b VP receptors and a strong V1b selectivity for the rat species. On AtT20 cells stably transfected with the rat V1b receptor, d[Leu4, Lys8]VP behaved as a full agonist on both phospholipase C and MAPK assays. Additional experiments revealed its ability to induce the internalization of enhanced green fluorescent protein-tagged human and mouse V1b receptors as expected for a full agonist. Additional physiological experiments were performed to further confirm the selectivity of this peptide. Its antidiuretic, vasopressor, and in vitro oxytocic activities were weak compared with those of VP. In contrast, used at low doses, its efficiency to stimulate adrenocorticotropin or insulin release from mouse pituitary or perfused rat pancreas, respectively, was similar to that obtained with VP. In conclusion, d[Leu4, Lys8]VP is the first selective agonist available for the rat V1b VP receptor. It will allow a better understanding of V1b receptor-mediated effects in rodents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308
Cloning and characterization of the human V3 pituitary vasopressin receptor
de Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertagna, X., & Clauser, E. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01268-7 · Cited by 209
The oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism
Reversi, A., Rimoldi, V., Marrocco, T., Cassoni, P., Bussolati, G., Parenti, M., & Chini, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409945200 · Cited by 139
Oshikawa, S., Tanoue, A., Koshimizu, T.-A., Kitagawa, Y., & Tsujimoto, G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.623 · Cited by 105
Abu-Basha, E. A., Yibchok-anun, S., & Hsu, W. H. (2002) · Metabolism · doi:10.1053/meta.2002.34052 · Cited by 80
Derick, S., Cheng, L. L., Voirol, M. J., Stoev, S., Giacomini, M., Wo, N. C., Szeto, H. H., Ben Mimoun, M., Andres, M., Gaillard, R. C., et al. (2002) · Endocrinology · doi:10.1210/en.2002-220363 · Cited by 76
Folny, V., Raufaste, D., Lukovic, L., Pouzet, B., Rochard, P., Pascal, M., & Serradeil-Le Gal, C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00148.2003 · Cited by 61
Vasopressin: A potent autocrine/paracrine regulator of mammal adrenal functions.
Guillon, G., Grazzini, E., Andrez, M., Breton, C., Trueba, M., Gal, C. S.-L., Boccara, G., Derick, S., Chouinard, L., & Gallo-payet, N. (1998) · Endocrine Research · doi:10.3109/07435809809032672 · Cited by 55
Self-citationFujiwara, Y., Hiroyama, M., Sanbe, A., Yamauchi, J., Tsujimoto, G., & Tanoue, A. (2007) · Journal of Endocrinology · doi:10.1677/joe.1.06864 · Cited by 36
Cited by
Vasopressin: Behavioral roles of an “original” neuropeptide
Caldwell, H. K., Lee, H.-J., Macbeth, A. H., & Young, W. S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.007 · Cited by 504
“…nM values for KD (Oxt values) or Ki at the specific rat receptor (s=agonist, i=antagonist where known) except for SRX251 (human) References: 1 Pena et al., 2007a 2 Manning and Sawyer, 1993 3 Saito et al., 1997 4 Antoni, 1984 5 Howl et al., 1993 6 Antoni and Chadio, 1989 7 Guillon et al.,…”
BackgroundOxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423
Self-citationMANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296
Self-citationCHINI, B., MANNING, M., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00438-x · Cited by 65
Self-citationBrain vasopressin signaling modulates aspects of maternal behavior in lactating rats
Bayerl, D. S., & Bosch, O. J. (2019) · Genes, Brain and Behavior · doi:10.1111/gbb.12517 · Cited by 46
Metadata
- Authors
- Pena, A., Murat, B., Trueba, M., Ventura, M. A., Bertrand, G., Cheng, L. L., Stoev, S., Szeto, H. H., Wo, N., Brossard, G., Serradeil-Le Gal, C., Manning, M., & Guillon, G.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-09-01
- Volume
- 148
- Issue
- 9
- Pages
- 4136-4146
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2164768810
- Cited by
- 37
- References
- 11
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.